InflaRx N.V. (IFRX) Begins Second Phase II Clinical Trial of IFX-1 in ANCA-Associated Vasculitis with First Patient Treated in Europe

May 14, 2019 8:01 AM EDT

Send to a Friend

InflaRx (NASDAQ: IFRX) today announced the treatment of the first patient in IXchange, a Phase II study with IFX-1 in …

This is a premium only article. To continue reading this article and more like it please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *